INTRODUCTION
Coronavirus disease (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since the first incidence of SARS-CoV-2 infection was discovered in December 2019 in Wuhan, Hubei Province, China, the disease has escalated at an alarming rate.1,2 As of 1 November 2021, World Health Organization (WHO) had confirmed 246,357,468 cases of COVID-19 worldwide, including 4,995,412 casualties.3 While the causative SARS-CoV-2 virus predominantly affects the respiratory system, problems in other organ systems, such as the cardiovascular, neurologic, and renal, can also contribute to disease fatality.4,5
In a previous study in China, 344 patients with COVID-19 were admitted to the intensive care unit. One hundred thirty-three people died on the 28th day, with a median survival of 25 days. Numerous patients have a variety of comorbidities.6 Additionally, another study in China found that 247 of 633 COVID-19 patients had at least one comorbidity.7
In Indonesia, data on medical comorbidities and COVID-19 prognosis are limited. The objective of this study is to evaluate the relation of comorbidities to COVID-19 short-term mortality. Additionally, we would like to investigate the relationship between specific comorbidities and COVID-19 short-term mortality.